Hyloris Pharmaceuticals (HYL) Stock Overview
Operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HYL from our risk checks.
HYL Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Hyloris Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.20 |
| 52 Week High | €8.40 |
| 52 Week Low | €4.11 |
| Beta | 0.64 |
| 1 Month Change | -6.67% |
| 3 Month Change | -8.70% |
| 1 Year Change | -30.23% |
| 3 Year Change | -64.10% |
| 5 Year Change | -69.45% |
| Change since IPO | -59.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| HYL | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | -1.2% | 3.1% | 0.7% |
| 1Y | -30.2% | 9.8% | 20.2% |
Return vs Industry: HYL underperformed the Belgian Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: HYL underperformed the Belgian Market which returned 20.2% over the past year.
Price Volatility
| HYL volatility | |
|---|---|
| HYL Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in BE Market | 7.4% |
| 10% least volatile stocks in BE Market | 2.0% |
Stable Share Price: HYL has not had significant price volatility in the past 3 months compared to the Belgian market.
Volatility Over Time: HYL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 55 | Stijn Van Rompay | hyloris.com |
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder; XTRAZA and Tranexamic Acid IV RTU for the prevention and treatment of excessive bleeding; HY-094 Iron IV to treat iron deficiency; and Pantoprazole IV for short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis.
Hyloris Pharmaceuticals SA Fundamentals Summary
| HYL fundamental statistics | |
|---|---|
| Market cap | €117.60m |
| Earnings (TTM) | -€6.33m |
| Revenue (TTM) | €7.94m |
Is HYL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYL income statement (TTM) | |
|---|---|
| Revenue | €7.94m |
| Cost of Revenue | €379.00k |
| Gross Profit | €7.56m |
| Other Expenses | €13.89m |
| Earnings | -€6.33m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 24, 2026
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 95.23% |
| Net Profit Margin | -79.78% |
| Debt/Equity Ratio | 0.2% |
How did HYL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 06:57 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hyloris Pharmaceuticals SA is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Allen | Berenberg |
| David Seynnaeve | Degroof Petercam |
| Jacob Mekhael | KBC Securities NV |